Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

US7812019B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Arthur Gomtsyan · Vernon Hills, US
• Erol K. Bayburt · Gurnee, US
• Robert G. Schmidt · Waukegan, US
• Chih-Hung Lee · Vernon Hills, US
• Brian S. Brown · Evanston, US
• Tammie K. Jinkerson · Pleasant Prairie, US
• John R. Koenig · Chicago, US
• Jerome F. Daanen · Racine, US
• Steven P. Latshaw · Round Lake, US

Key dates

• Filing date: Nov 22, 2005
• Grant date: Oct 12, 2010
• Expiry date: Mar 21, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds that are antagonists of the VR1 receptor, having formula (I)or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.